


Author's Accepted Manuscript

Gene Therapy for Hemophilia: Past, Present and Future

L.A. George MD, Patrick F. Fogarty MD



www.elsevier.com/locate/enganabound

PII: S0037-1963(15)00080-3
DOI: <http://dx.doi.org/10.1053/j.seminhematol.2015.10.002>
Reference: YSHEM50837

To appear in:
Semin Hematol

Cite this article as: L.A. George MD, Patrick F. Fogarty MD, Gene Therapy for Hemophilia: Past, Present and Future, *Semin Hematol* , <http://dx.doi.org/10.1053/j.seminhematol.2015.10.002>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Gene Therapy for Hemophilia: Past, Present and Future
L. A. George, MD^{a,b,c} and Patrick F. Fogarty, MD^{a,d,e}

^a *Division of Hematology, The Children's Hospital of Philadelphia, Philadelphia, PA*

^b *Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA*

^c *Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA*

^d *Penn Comprehensive Hemophilia and Thrombosis Program, Hospital of the University of Pennsylvania, Philadelphia, PA*

^e *Division of Hematology/Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA*

Corresponding Author:

Lindsey A. George, M.D.
The Children's Hospital of Philadelphia
Division of Hematology
CTRB, Room 5016
3501 Civic Center Boulevard
Philadelphia, PA 19104
Tel: 267-432-2664
Fax: 215-590-3660
greene@email.chop.edu

Running title: Gene Therapy and Hemophilia

Financial Disclosure:

Lindsey A. George: The author declares that she has no conflicts of interest or competing financial or personal relationships that could inappropriately influence the content of this article.

Patrick F. Fogarty: Dr. Fogarty has received consulting fees from Bayer Healthcare, Baxter/Baxalta, Biogen, Chugai, CSL Behring, NovoNordisk, and Pfizer, Inc.; has received research support from Bayer Healthcare, Baxter/Baxalta, Biogen, CSL Behring, Pfizer, Inc. and Spark Therapeutics; and is an employee of Pfizer, Inc.

Download English Version:

<https://daneshyari.com/en/article/3333445>

Download Persian Version:

<https://daneshyari.com/article/3333445>

[Daneshyari.com](https://daneshyari.com)